The present study investigated the prophylactic efficacy of
fluconazole at 100-200 mg/day against
invasive fungal infections during
bone marrow transplantation (BMT). During July 1990 to December 1991, all BMT recipients received antifungal prophylaxis with
fluconazole at either 200 mg/day or 100 mg/day. Historical controls were those that received no antifungal prophylaxis (January 1989 to June 1990).
Fungemia occurred in 4 of 112
fluconazole recipients and 8 of 79 controls (p < 0.05) prior to engraftment.
Torulopsis (Candida) glabrata (three patients), Cryptococcus terreus and Candida tropicalis (mixed in one patient) caused
fungemia in four patients in the
fluconazole group; Candida albicans caused six of eight fungemic episodes in the controls. All three Torulopsis glabrata isolates were
fluconazole-resistant. Colonization due to C. albicans was markedly diminished in the
fluconazole group (19 of 112 patients versus 53 of 79 controls). T. glabrata, on the other hand, was a more common colonizing organism in the
fluconazole group (36 of 112 vs 10 of 79). The frequency of isolating C. albicans and/or T. glabrata was significantly different between
fluconazole and control groups (p < 0.0001). Empiric use of
amphotericin B therapy was markedly reduced in the
fluconazole group (4.5% vs 34%; p < 0.0001).
Fluconazole at 200 mg/day or 100 mg/day appeared equally effective.
Fluconazole at a daily dose of 100 mg or 200 mg as antifungal prophylaxis during BMT: (1) significantly reduced the frequency of systemic
fungal infections, (2) markedly reduced colonization and
infection due to C. albicans, and (3) markedly reduced the need for empiric
amphotericin B therapy.(ABSTRACT TRUNCATED AT 250 WORDS)